BBNX (Beta Bionics) Ending Cash Position: $44.4 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BBNX Beta Bionics Inc BBNX
13 GF Score
Price $19.42
! 3 Warning Signs
View Full Analysis

What is Beta Bionics Ending Cash Position?

Beta Bionics BBNX -2.51% 13 Ending Cash Position is $44.4 Mil as of Jun. 2026. GuruFocus rates BBNX with a GF Score™ of 13/100. The stock has 3 warning signs investors should review.

Beta Bionics's Ending Cash Position for the quarter that ended in Jun. 2026 was $44.4 Mil.

Beta Bionics's quarterly Ending Cash Position declined from Dec. 2025 ($31.7 Mil) to Mar. 2026 ($30.3 Mil) but then increased from Mar. 2026 ($30.3 Mil) to Jun. 2026 ($44.4 Mil).

Beta Bionics's annual Ending Cash Position increased from Dec. 2023 ($26.7 Mil) to Dec. 2024 ($30.5 Mil) and increased from Dec. 2024 ($30.5 Mil) to Dec. 2025 ($31.7 Mil).

Beta Bionics Ending Cash Position Related Terms

Beta Bionics Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Beta Bionics's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Beta Bionics Ending Cash Position Chart

Beta Bionics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Ending Cash Position
27.78 26.67 30.53 31.68

Beta Bionics Quarterly Data
Dec22 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 35.18 38.59 31.68 30.31 44.42
BBNX
13GF Score
Beta Bionics Inc BBNX
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Beta Bionics Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Beta Bionics's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=30.532+1.144
=31.7

Beta Bionics's Ending Cash Position for the quarter that ended in Jun. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=30.306+14.112
=44.4

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $44.4 Mil mean?
Beta Bionics (BBNX) has a Ending Cash Position of $44.4 Mil as of Jun. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Beta Bionics and its competitors.
Is Beta Bionics' Ending Cash Position too high?
Beta Bionics' current Ending Cash Position is $44.4 Mil. Overall, Beta Bionics has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Beta Bionics' Ending Cash Position compare to CBLL and SIBN?
Beta Bionics' Ending Cash Position of $44.4 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Medical Devices & Instruments company?
A good Ending Cash Position depends on the Medical Devices & Instruments industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Beta Bionics and its competitors. Beta Bionics's current Ending Cash Position is $44.4 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beta Bionics stock overvalued right now?
Beta Bionics (BBNX) has a current Ending Cash Position of $44.4 Mil. The current Ending Cash Position is $44.4 Mil. Beta Bionics' overall GF Score™ is 13/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Beta Bionics (BBNX), the current Ending Cash Position is $44.4 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Beta Bionics Business Description

Address 11 Hughes, Irvine, CA, USA, 92618
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company's product includes the iLet Bionic Pancreas (iLet). The company operates as a single segment, focused on the development, manufacture, and sale of the iLet.
13GF Score

Get the complete analysis for BBNX

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$19.42
Price